Quantification of Urinary Protein Biomarkers of Autosomal Dominant Polycystic Kidney Disease by Parallel Reaction Monitoring-Reference-Cited by-同舟云学术

Quantification of Urinary Protein Biomarkers of Autosomal Dominant Polycystic Kidney Disease by Parallel Reaction Monitoring

Published:2018-05-02 Issue:5 Volume:12 Page:1700157
ISSN:1862-8346
Container-title:PROTEOMICS - Clinical Applications
language:en
Short-container-title:Prot. Clin. Appl.

Author:

Rauniyar Navin¹²,Yu Xiaoqing³,Cantley Jennifer⁴,Voss Edward Z.²,Belcher Justin⁴,Colangelo Christopher M.²,Stone Kathryn L.²,Dahl Neera⁴,Parikh Chirag⁴⁵,Lam TuKiet T.¹²,Cantley Lloyd G.⁴

Affiliation:

1. Department of Molecular Biophysics and Biochemistry; Yale University School of Medicine; 06520 New Haven CT USA

2. MS and Proteomics Resource; W.M. Keck Biotechnology Resource Laboratory; Yale University School of Medicine; 06511 New Haven CT USA

3. Department of Biostatistics and Bioinformatics; H. Lee Moffitt Cancer Center and Research Institute; 33612 Tampa FL USA

4. Section of Nephrology; Yale University School of Medicine; 06520 New Haven CT USA

5. Program of Applied Translational Research; Yale University School of Medicine; 06520 New Haven CT USA

Funder

National Institutes of Health

Publisher

Wiley

Subject

Clinical Biochemistry

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/prca.201700157/fullpdf

Reference29 articles.

1. Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

2. Autosomal Dominant Polycystic Kidney Disease

3. Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent progress in mass spectrometry-based urinary proteomics;Clinical Proteomics;2024-02-22

2. Inhibiting centrosome clustering reduces cystogenesis and improves kidney function in autosomal dominant polycystic kidney disease;JCI Insight;2024-02-22

3. Introduction to sample preparation for proteomics and mass spectrometry;Proteomics Mass Spectrometry Methods;2024

4. Quantitative comparison of the renal pelvic urine and bladder urine to examine modifications of the urine proteome by the lower urinary tract;PROTEOMICS – Clinical Applications;2023-08-13

5. Proteomic Approaches and Potential Applications in Autosomal Dominant Polycystic Kidney Disease and Fabry Disease;Diagnostics;2023-03-17